Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 19:16:1687-1701.
doi: 10.2147/PPA.S366522. eCollection 2022.

Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study

Simon Fifer  1 , Brittany Keen  1 , Richard Newton  2 , Andrea Puig  3 , Marija McGeachie  4
Affiliations

Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study

Simon Fifer et al. Patient Prefer Adherence. .

Abstract

Purpose: To examine the treatment and long-term outcome preferences for people living with schizophrenia.

Patients and methods: Sixty-six Australian adults, living with schizophrenia completed a novel online survey with six sections: Demographic characteristics; Disease history; Quality-of-life; Patient support programmes; Discrete Choice Experiment, and Best-Worst Scaling exercise.

Results: Participants indicated that they preferred to be involved in treatment decision with their doctor. A minority of participants reported having been previously involved in a patient support programme (28.8%) and only one in six participants had a National Disability Insurance Scheme (NDIS) package (16.7%) with over a third of participants indicating that they were ineligible (37.9%). Participants' average quality-of-life score was 60%.

Conclusion: Recent hospitalisation influenced the relative importance of treatment attributes, with effectiveness on hearing voices being the most important treatment attribute. The most important long-term goals were having a stable place to live, being independent, and physical health. People with schizophrenia care about their long-term functional recovery outcomes, rating symptom control and independence as their highest priority. They want to be part of the treatment conversation with their doctors. Therefore, psychiatrists are encouraged to use shared decision-making to establish the treatment course that best aligns with individuals' long-term goals.

Keywords: discrete choice experiment; patient preference; patient value mapping; schizophrenia; shared decision-making; treatment goals.

PubMed Disclaimer

Conflict of interest statement

S Fifer and B Keen are employed by CaPPRe. CaPPRe has consulted to AbbVie, Amgen, AstraZeneca, Celgene, CSL Behring, Edwards, GSK, Ipsen, Janssen, Novo Nordisk, Roche, Sanofi, Shire and UCB, outside of the submitted work. A Puig and M McGeachie are employees of Janssen-Cilag Australia Pty Ltd. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
(A) Attribute importance for those hospitalised in the past two year. (B) Attribute importance for those not hospitalised in the past 2 years.
Figure 2
Figure 2
Best-Worst Scaling scores for long-term treatment outcomes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mueser KT, McGurk S. Schizophrenia. Lancet. 2004;363(9442):2063–2072. doi:10.1016/S0140-6736(04)16458-1 - DOI - PubMed
    1. Morgan VA, McGrath JJ, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med. 2014;44(10):2163–2176. doi:10.1017/S0033291713002973 - DOI - PMC - PubMed
    1. Galletly C, Castle DJ, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):1–117. doi:10.1177/0004867416641195 - DOI - PubMed
    1. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404. doi:10.1016/s2215-0366(21)00039-0 - DOI - PubMed
    1. Lindenmayer JP, Glick ID, Talreja H, Underriner M. Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol. 2020;40(4):346–349. doi:10.1097/JCP.0000000000001225 - DOI - PubMed